XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Collaboration Agreements, License Agreement and Revenues - Product Revenue, Net - Additional Information 1 (Detail) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total revenue $ 50,641 $ 44,319 $ 106,544 $ 80,480  
Contract with Customer, Liability [Abstract]          
Deferred revenue, net of current 131,192   131,192   $ 157,555
Net unbilled milestone and co-development revenue 0   0   0
Constrained for Future Recognition [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total revenue 18,100 3,300 20,600 1,200  
Product Revenue, Net [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total revenue 49,643 $ 23,889 80,181 $ 48,049  
China [Member] | Product Revenue, Net [Member]          
Contract with Customer, Liability [Abstract]          
Contract with customer liability increase decrease in revenue due to changes to estimated variable consideration 12,200        
AstraZeneca Agreements [Member]          
Contract with Customer, Liability [Abstract]          
Deferred Revenue 158,593   158,593   179,851
Deferred revenue, net of current 131,300   131,300    
Net unbilled milestone and co-development revenue 23,300   23,300   22,500
AstraZeneca Agreements [Member] | China performance obligation [Member]          
Contract with Customer, Liability [Abstract]          
Deferred Revenue 158,600   158,600    
Net unbilled milestone and co-development revenue 27,300   27,300    
AstraZeneca Agreements [Member] | China [Member]          
Contract with Customer, Liability [Abstract]          
Deferred Revenue 3,400   3,400    
Beijing Falikang Pharmaceutical Co Ltd | Product Revenue, Net [Member]          
Contract with Customer, Liability [Abstract]          
Reductions to gross accounts receivable $ 2,300   $ 2,300   $ 3,000